Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

NCT06617923 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Ovary Cancer
Fallopian Tube Cancer
Primary Peritoneal Cavity Cancer

Interventions

DRUG: Senaparib
DRUG: Temozolomide

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]